Pricing Log in Create free account
Friday 6 November 2026 Export BMRN’s income statement to Excel — free account

BioMarin Pharmaceutical Inc.

BMRN Healthcare Biotechnology

BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.

Revenue
+32.0%
EPS
−296.6%
Free cash flow
−52.3%
Total debt
+599.5%

Quarter to September 2026, against a year earlier

55.73 0.39 −0.69%
Market cap
$10.9B
P/E
0.0×
Fwd P/E
32.7×
Dividend yield
—
F-score
5/9
Altman Z
5.67
Beneish M
−2.49
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

BioMarin Pharmaceutical Inc. 8-K filed Apr 27, 2026

Period ended Apr 27, 2026 · Filed · accepted 8:45 AM ET · Document on sec.gov · Filing index

1.01 Entry into a material definitive agreement; 2.01 Completion of an acquisition or disposition; 2.03 Creation of a direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov